PreveCeutical Announces Management Cease Trade Order
PreveCeutical Announces Management Cease Trade Order
Vancouver, British Columbia--(Newsfile Corp. - May 2, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that the Company has missed the filing deadline of April 29, 2024 to file the Company's audited annual financial statements and accompanying management's discussion and analysis, with related CEO and CFO certificates, for the financial year ended December 31, 2023 (collectively, the "Annual Filings"), as required under applicable Canadian securities laws.
不列颠哥伦比亚省温哥华--(Newsfile Corp.-2024 年 5 月 2 日)- preveCeutical Medical Inc (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the”公司“或”preveCeutical“)宣布,公司错过了2024年4月29日的申报截止日期,无法提交截至2023年12月31日的财政年度的公司经审计的年度财务报表和随附的管理层讨论和分析以及相关的首席执行官和首席财务官证书(统称为”年度申报“),根据适用的加拿大证券法的要求。
In connection with the Company's inability to file the Annual Filings on time, the Company applied for a Management Cease Trade Order ("MCTO") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203") and the MCTO was issued by the British Columbia Securities Commission effective as of May 2, 2024.
由于公司无法按时提交年度申报,公司申请了管理层停止交易令(”MCTO“) 根据国家政策 12-203- 管理层停止交易订单 (”NP 12-203“),MCTO 由不列颠哥伦比亚省证券委员会发布,自2024年5月2日起生效。
The Company was unable to file its Annual Filings within the required time due to a lack of funds, which prevented the Company from engaging its auditors and completing its audit in a timely manner. The Company expects to file the Annual Filings as soon as they are available, but in any event no later than June 28, 2024.
由于缺乏资金,公司无法在规定的时间内提交年度申报,这使公司无法聘请审计师和及时完成审计。该公司预计将在年度申报发布后尽快提交,但无论如何都不迟于2024年6月28日。
The Company will issue a news release once the Annual Filings have been filed. Until the Company files the Annual Filings, it will comply with the alternative information guidelines set out in NP 12-203. The guidelines, among other things, require the Company to issue bi-weekly default status reports, in the form of news releases, for so long as the Annual Filings have not been filed.
提交年度申报后,公司将发布新闻稿。在公司提交年度申报之前,它将遵守NP 12-203中规定的替代信息指南。除其他外,该指导方针要求公司每两周以新闻稿的形式发布违约状态报告,前提是年度申报尚未提交。
The Company also anticipates completing a private placement for gross proceeds of up to $250,000 (the "Proposed Private Placement") in the near future, and expects to use the proceeds of the Proposed Private Placement for working capital purposes, including payment of audit related fees. The Company will provide further details on the Proposed Private Placement in a subsequent news release.
该公司还预计将完成私募配售,总收益高达25万美元(”拟议的私募配售“)在不久的将来,并预计将拟议私募的收益用于营运资金用途,包括支付审计相关费用。该公司将在随后的新闻稿中提供有关拟议私募的更多细节。
During the MCTO, the general investing public will continue to be able to trade in the Company's common shares (the "Shares") listed on the Canadian Securities Exchange. However, the Company's CEO, CFO and such other directors, officers and persons as determined by the applicable regulatory authorities will not be able to trade in the Shares, nor will the Company be able to, directly or indirectly, issue securities to or acquire securities from an insider or employee of the Company except in accordance with legally binding obligations to do so existing as of April 29, 2024, being the date of the Company's anticipated continuous disclosure default.
在MCTO 期间,普通投资公众将继续能够交易公司的普通股(”股份“)在加拿大证券交易所上市。但是,公司的首席执行官、首席财务官以及相关监管机构确定的其他董事、高级管理人员和人员将无法交易股票,也无法直接或间接向公司内部人士或员工发行证券或从公司内部人士或员工那里收购证券,除非根据截至2024年4月29日,即公司预期的持续披露违约之日存在的具有法律约束力的义务。
The Company is not subject to any insolvency proceedings. If the Company provides any information to any of its creditors during the period in which it is in default of filing the Annual Filings, the Company confirms that it will also file material change reports on SEDAR+ containing such information.
公司不受任何破产程序的约束。如果公司在未提交年度申报期间向任何债权人提供任何信息,则公司确认还将在SEDAR+上提交包含此类信息的重大变更报告。
About PreveCeutical
关于 PreveUtical
PreveCeutical is a health sciences company focused on developing innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector.
preveCeutical是一家健康科学公司,致力于利用有机和自然相同的产品为预防和治疗疗法开发创新的选择。该公司的目标是成为预防健康科学领域的领导者。
With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs.
随着三项研究计划的完成,该公司正在积极致力于其产品的开发、临床试验和商业化;并已提交了多项临时专利申请,以保护知识产权免受其研究计划的影响。
For more information about PreveCeutical, please visit our website or follow us on Twitter and Facebook.
有关PreveCeutical的更多信息,请访问我们的网站或在推特和脸书上关注我们。
On behalf of the Board of Directors of PreveCeutical
代表 preveCeutical 董事会
Stephen Van Deventer, Chairman, Chief Executive Officer and interim Chief Financial Officer
Stephen Van Deventer,董事长、首席执行官兼临时首席财务官
For further information, please contact:
欲了解更多信息,请联系:
Stephen Van Deventer: +1 604 306 9669
Stephen Van Deventer:+1 604 306 9669
Or Investor Relations ir@preveceutical.com
或者投资者关系 ir@preveceutical.com
Forward-Looking Statements
前瞻性陈述
Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified using forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to, among other things: the Company's Proposed Private Placement; the Company's plans relating to the development, clinical trials and commercialization of its products; management expectations that it will be able to file the Annual Filings within the time period described herein.
关于前瞻性陈述的警示说明:本新闻稿包括某些陈述和信息,这些陈述和信息可能构成适用的加拿大证券法所指的前瞻性信息。前瞻性陈述与未来事件或未来业绩有关,反映了公司管理层对未来事件的期望或信念。通常,可以使用诸如 “打算” 或 “预期” 之类的前瞻性术语来识别前瞻性陈述和信息,或者某些行为、事件或结果 “可能”、“应该”、“将” 或 “发生” 的此类词语和短语或陈述的变体。这些信息和这些陈述(此处称为 “前瞻性陈述”)不是历史事实,是截至本新闻发布之日作出的,包括但不限于关于未来计划、估计和预测讨论的声明,以及关于管理层对以下方面的预期和意图的陈述:公司拟议的私募配售;公司与产品开发、临床试验和商业化有关的计划;管理层对其的期望将能够提交在本文所述的时间段内提交年度申报。
These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the Company being unable to execute its business plans as intended; the Company being unable to file the Annual Filings in the proposed timeframe; the Company being unable to complete the Proposed Private Placement; recent market volatility; and the state of the financial markets for the Company's securities.
这些前瞻性陈述涉及许多风险和不确定性,实际结果可能与任何前瞻性陈述中建议的结果存在重大差异。除其他外,这些风险和不确定性包括:公司无法按预期执行其业务计划;公司无法在拟议的时间范围内提交年度申报;公司无法完成拟议的私募配售;最近的市场波动;以及公司证券的金融市场状况。
In making the forward-looking statements in this news release, the Company has applied certain material assumptions, including without limitation, that: the Company will be able to execute its business plans as intended; the Company will be able to file the Annual Filings in the proposed time frame.
在本新闻稿中发表前瞻性陈述时,公司运用了某些重要假设,包括但不限于:公司将能够按预期执行其业务计划;公司将能够在拟议的时间范围内提交年度申报。
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
尽管公司管理层试图确定可能导致实际业绩与前瞻性陈述或前瞻性信息中包含的结果存在重大差异的重要因素,但可能还有其他因素导致业绩不如预期、估计或预期。无法保证此类陈述会被证明是准确的,因为实际结果和未来事件可能与此类声明中的预期存在重大差异。因此,读者不应过分依赖前瞻性陈述和前瞻性信息。提醒读者,依赖此类信息可能不适合用于其他目的。除非符合适用的证券法,否则公司不承诺更新此处以引用方式纳入的任何前瞻性陈述、前瞻性信息或财务展望。我们寻求安全港。